Spinal Muscular Atrophy (SMA) Caenorhabditis elegans Model Development Service

Creative Biolabs provides custom spinal muscular atrophy (SMA) Caenorhabditis elegans model development for studies of SMN deficiency, neuromuscular dysfunction, RNA-processing defects, genetic modifiers, target validation, and early therapeutic screening.

Projects can be connected with our C. elegans model development services, the broader spinal muscular atrophy model development service, and the A-Z™ SMA drug discovery platform.

Select the Right smn-1 Perturbation and Rescue Architecture

A balanced smn-1 null strain can expose strong SMN-dependent developmental and neuromuscular phenotypes, but maternal SMN-1 contribution and early lethality require careful staging. Partial depletion, conditional control, tissue-specific rescue, or sensitized backgrounds can create longer windows for target engagement and pharmacology. Human SMN1 or SMN2-derived constructs can be used to examine conservation or rescue, provided the construct, expression pattern, copy behavior, and interpretation are explicitly qualified.

When a project requires customized expression control, strain engineering can be integrated with our C. elegans transgenic modeling service or C. elegans overexpression model development service.

Generate, Stabilize, and Genetically Qualify the Strain

Development is organized around acceptance criteria that link genotype, expression, phenotype, and intended use. A strain is not advanced on PCR identity alone, it must behave consistently under the planned culture, staging, imaging, and dosing conditions.

Genetic Design and Editing Strategy

The design package defines the smn-1 allele or knockdown region, rescue or reporter construct, promoter and untranslated regions, tag or fluorescent marker, integration method, selectable or co-injection marker, host strain, balancer strategy, and downstream assay requirements. CRISPR/Cas editing, transgenic arrays or integrations, RNAi, and genetic crosses can be configured according to the desired expression context. For human constructs, the workflow also specifies transcript design, coding sequence, isoform or exon context, and any variant or domain comparison.

Founder Recovery, Balancing, and Line Establishment

Candidate animals are screened for the intended edit or transgene, propagated through defined generations, and evaluated for transmission, stability, viability, fertility, and marker behavior. Severe smn-1 loss may require a balancer chromosome and genotype-aware propagation. Multiple independent lines can be retained to distinguish construct biology from insertion, mosaicism, background, or founder-specific effects. Confirmed strains may be outcrossed, expanded, cryopreserved, and transferred with genotype and culture documentation.

Genetic, Expression, and Functional Qualification

Qualification can include junction PCR, amplicon or Sanger sequencing, copy-number assessment where relevant, zygosity determination, transgene integration and segregation analysis, RNA quantification, protein or fluorescence measurement, tissue localization, and initial rescue or loss-of-function phenotyping. The exact panel is matched to the architecture: a tissue-specific rescue model requires localization and functional rescue evidence, while a partial-depletion model requires quantitative residual expression and a stable, gradable phenotype.

Background, Developmental Stage, and Assay Controls

SMA-related worm phenotypes can change with maternal contribution, balancer background, larval stage, temperature, food source, plate age, population density, developmental synchronization, handling, and imaging settings. The study plan therefore defines common-background controls, matched maternal and balancer conditions where appropriate, stage or time-after-hatch criteria, replicate structure, exclusion rules, normalization, and blinded analysis when practical.

Build a Decision-Ready Neuromuscular and Molecular Phenotype Map

Rather than maximizing the number of readouts, we connect a primary endpoint to orthogonal evidence of genetic identity, SMN biology, organismal health, neuromuscular function, and molecular mechanism.

• Locomotion and neuromuscular performance. Body bends, crawling velocity, track morphology, thrashing, reversal behavior, touch response, posture, paralysis kinetics, pharyngeal pumping, and project-specific stimulus-response assays can capture motor and synaptic consequences. Automated tracking or high-content imaging can support throughput and reduce operator bias.
• Development, fitness, and survival. Larval progression, body length, time to adulthood, developmental arrest, fertility, brood size, food clearance, stress sensitivity, healthspan, and lifespan help distinguish specific neuromuscular rescue from nonspecific growth or toxicity effects.
• Neuronal, synaptic, and muscle morphology. Fluorescent markers and microscopy can evaluate motor-neuron architecture, axons, neurite continuity, synaptic puncta, neuromuscular junction organization, muscle structure, mitochondrial morphology, and reporter-defined cellular stress. Image-analysis thresholds and acquisition settings are prespecified.
• SMN biology and molecular mechanism. Readouts may include smn-1 transcript or protein, transgene expression, snRNP- or splicing-related endpoints, RT-qPCR, targeted splice assays, RNA sequencing, differential gene expression, pathway analysis, mitochondrial and vacuolar ATPase signatures, histone-transcript changes, and project-specific biomarkers.
• Target engagement and rescue. Genetic, transgenic, RNAi, or pharmacological interventions are evaluated against predefined rescue criteria. An apparent improvement in movement is interpreted alongside exposure, genotype, organismal fitness, reporter behavior, and at least one orthogonal endpoint whenever feasible.
• Safety and assay interference. Compound precipitation, bacterial effects, altered feeding, fluorescence interference, developmental delay, sedation, and general toxicity can mimic or obscure rescue. Counter-screens and wild-type exposure controls are included according to the test article and assay format.

Scalable locomotor, fluorescence, and morphology workflows can be extended through our C. elegans high-content phenotypic screening assay service.

Model Development, Screening, and Integrated Deliverables

1. Scientific alignment. Define the SMA mechanism, model purpose, intervention class, translational claim, primary endpoint, comparator strains, developmental window, throughput, and go/no-go criteria.
2. Model and assay design. Select the smn-1 perturbation, rescue or reporter architecture, host background, balancer, controls, culture conditions, genotyping plan, assay hierarchy, and data-normalization strategy.
3. Strain generation and qualification. Recover candidate lines, verify sequence or construct identity, confirm transmission and stability, quantify expression or depletion, outcross when appropriate, and retain independent lines or a backup strategy.
4. Phenotype-window mapping. Run age- or stage-resolved studies to establish effect size, variability, assay dynamic range, repeatability, sample-size assumptions, and the relationship among developmental, behavioral, cellular, and molecular endpoints.
5. Pilot intervention and exposure optimization. Evaluate delivery method, concentration range, exposure duration, vehicle tolerance, food-mediated effects, positive or reference controls, and assay interference before scaling.
6. Screening or efficacy execution. Randomize plate positions and processing order where practical, use biological replicates and prespecified QC, monitor wild-type and disease controls, acquire primary and secondary endpoints, and preserve samples for confirmatory analysis.
7. Integrated analysis and reporting. Deliver methods, strain and construct records, QC results, raw and processed data, statistical outputs, representative images, phenotype and rescue interpretation, limitations, and recommended follow-up experiments.

Decision-ready hits or mechanisms can be advanced into SMA mouse model development, SMA zebrafish model development, or a broader neurological disease modeling and drug efficacy testing service.

Related Research

Zygotic smn-1 Loss Reveals Broad Expression and Splicing Disruption

Rashid and colleagues profiled smn-1(ok355) animals against wild-type controls derived from a shared hT2 background. They reported thousands of expression changes and more than 1,000 alternative splicing events, with exon skipping and intron retention prominent among the altered classes. The study reinforces the need to match genetic background and developmental stage, and it provides a framework for pairing organismal phenotypes with targeted or transcriptome-wide RNA-processing endpoints.

Fig. 1 Zygotic loss of SMN-1 causes large-scale gene-expression and splicing changes in a C. elegans SMA model.^1,3

Early Transcriptomic Profiling Identifies Mitochondrial and V-ATPase Signatures

Gao and colleagues analyzed an smn-1(ok355) model before overt late-stage decline and identified a distinct transcriptional profile. Differentially expressed genes included broad changes in nuclear-encoded mitochondrial genes, vacuolar H+-ATPase genes, and histone genes.

Fig. 2 RNA sequencing identifies differential gene-expression patterns in smn-1(ok355) and related C. elegans genotypes.^2,3

Frequently Asked Questions

1. What SMA C. elegans models can Creative Biolabs develop?

   Creative Biolabs can develop balanced smn-1 loss-of-function strains, calibrated partial-depletion or RNAi models, tissue-specific and inducible strategies, worm or human SMN rescue models, reporter and sensitized strains, and project-specific CRISPR allele series. The design is selected according to the mechanism, assay window, throughput, intervention, and translational question.

2. How do I choose between a severe smn-1 loss model and a partial-depletion model?

   A severe loss-of-function model can provide strong early developmental, survival, and neuromuscular signals but may have a narrow window because of maternal rescue and larval lethality. Partial depletion or a hypomorphic strategy can provide a longer and more gradable window for repeated measurement, chronic exposure, and pharmacological rescue. A pilot comparison can define the most decision-relevant architecture.

3. Can human SMN1 or SMN2 constructs be evaluated in C. elegans?

   Yes. Human SMN1, SMN2-derived, isoform, domain, or variant constructs may be introduced for conservation, rescue, or structure-function studies. Because C. elegans does not reproduce the human SMN1/SMN2 genomic context, the construct sequence, promoter, expression level, tissue distribution, copy behavior, and appropriate worm and human controls must be qualified before drawing translational conclusions.

4. Which phenotyping endpoints are available for SMA worm models?

   Programs can combine locomotion, thrashing, crawling, track analysis, pharyngeal pumping, stimulus response, paralysis kinetics, body length, developmental progression, fertility, survival, neuronal and muscle morphology, synaptic reporters, mitochondrial phenotypes, smn-1 expression, targeted splice assays, RT-qPCR, RNA sequencing, and project-specific molecular markers.

5. Can an SMA C. elegans model support compound or genetic-modifier screening?

   Yes. Qualified strains can support RNAi modifier studies, genetic crosses, candidate-gene validation, compound exposure, and high-content phenotypic screening. Screening plans include plate and batch controls, wild-type and disease comparators, exposure optimization, toxicity and feeding counter-screens, prespecified hit criteria, and orthogonal confirmation.

6. How are maternal rescue and developmental-stage effects controlled?

   The study can use balanced propagation, genotype-aware collection, synchronized populations, common-background controls, matched maternal and balancer conditions, defined time-after-hatch or larval-stage criteria, and stage-sensitive molecular analysis. Pilot time courses help identify a window in which genotype effects can be separated from general developmental delay.

7. Can the worm program be connected to vertebrate SMA models?

   Yes. C. elegans can provide rapid whole-animal evidence for target prioritization, modifier biology, mechanism, and initial compound ranking. Selected findings can then be tested in zebrafish or mouse SMA models with vertebrate motor-neuron anatomy, pharmacokinetics, tissue exposure, and translational efficacy endpoints.

8. What information is needed to start an SMA C. elegans model development project?

   Helpful inputs include the biological hypothesis, preferred smn-1 allele or perturbation, intervention class, human construct or variant if applicable, desired tissue and timing, primary endpoint, screening scale, comparator strains, molecular readouts, biospecimen needs, delivery constraints, timeline, and criteria for model acceptance or hit progression.

References

1. Rashid, Saman, et al. "Widespread Intron Retention and Exon Skipping Characterise Alternative Splicing Changes in a C. elegans Model of Spinal Muscular Atrophy." Human Molecular Genetics, vol. 35, no. 2, 2026, article ddaf176. https://doi.org/10.1093/hmg/ddaf176
2. Gao, Xiaoyang, et al. "Defective Expression of Mitochondrial, Vacuolar H+-ATPase and Histone Genes in a C. elegans Model of SMA." Frontiers in Genetics, vol. 10, 2019, article 410. https://doi.org/10.3389/fgene.2019.00410
3. Distributed under Open Access license CC BY 4.0, without modification